This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Antineoplaston A10
- DrugBank Accession Number
- DB11702
- Background
Antineoplaston A10 has been used in trials studying the treatment of Sarcoma, Lymphoma, Lung Cancer, Liver Cancer, and Kidney Cancer, among others.
- Type
- Small Molecule
- Groups
- Investigational
- Structure
Structure for Antineoplaston A10 (DB11702)
- Weight
- Average: 246.266
Monoisotopic: 246.100442319 - Chemical Formula
- C13H14N2O3
- Synonyms
- Antineoplaston A 10
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug eventsImprove clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events & improve clinical decision support.- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as n-acyl-alpha amino acids and derivatives. These are compounds containing an alpha amino acid (or a derivative thereof) which bears an acyl group at its terminal nitrogen atom.
- Kingdom
- Organic compounds
- Super Class
- Organic acids and derivatives
- Class
- Carboxylic acids and derivatives
- Sub Class
- Amino acids, peptides, and analogues
- Direct Parent
- N-acyl-alpha amino acids and derivatives
- Alternative Parents
- Phenylacetamides / Piperidinediones / Delta lactams / N-unsubstituted carboxylic acid imides / Dicarboximides / Secondary carboxylic acid amides / Azacyclic compounds / Organopnictogen compounds / Organonitrogen compounds / Organic oxides show 2 more
- Substituents
- Aromatic heteromonocyclic compound / Azacycle / Benzenoid / Carbonyl group / Carboxamide group / Carboxylic acid imide / Carboxylic acid imide, n-unsubstituted / Delta-lactam / Dicarboximide / Hydrocarbon derivative show 15 more
- Molecular Framework
- Aromatic heteromonocyclic compounds
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 16VY3TM7ZO
- CAS number
- 91531-30-5
- InChI Key
- OQGRFQCUGLKSAV-JTQLQIEISA-N
- InChI
- InChI=1S/C13H14N2O3/c16-11-7-6-10(13(18)15-11)14-12(17)8-9-4-2-1-3-5-9/h1-5,10H,6-8H2,(H,14,17)(H,15,16,18)/t10-/m0/s1
- IUPAC Name
- N-[(3S)-2,6-dioxopiperidin-3-yl]-2-phenylacetamide
- SMILES
- O=C(CC1=CC=CC=C1)N[C@H]1CCC(=O)NC1=O
References
- General References
- Not Available
- External Links
- PubChem Compound
- 56260
- PubChem Substance
- 347828067
- ChemSpider
- 50771
- ChEMBL
- CHEMBL1980825
- ZINC
- ZINC000001590366
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 2 Terminated Treatment Malignant Neoplasm of Colon 1 2 Withdrawn Treatment Adenocarcinoma of the Colon / Metastatic Colon Cancer / Recurrent Colon Cancer 1 2 Withdrawn Treatment Adenocarcinoma of the Prostate / Prostate Cancer - Recurrent / Stage III Prostate Cancer / Stage IV Prostate Cancer 1 2 Withdrawn Treatment Carcinoma Breast Stage IV / Recurrent Breast Cancer 2 2 Withdrawn Treatment Islet Cell Carcinoma / Merkel Cell Carcinoma / Neuroendocrine Carcinomas / Pituitary Neoplasms 1 2 Withdrawn Treatment Noncontiguous Stage II Mantle Cell Lymphoma / Recurrent Mantle Cell Lymphoma / Stage II Contiguous Mantle Cell Lymphoma / Stage III Mantle Cell Lymphoma / Stage IV Mantle Cell Lymphoma 1 2 Withdrawn Treatment Primary Central Nervous System Lymphoma (PCNSL) 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.304 mg/mL ALOGPS logP 0.37 ALOGPS logP 0.13 ChemAxon logS -2.9 ALOGPS pKa (Strongest Acidic) 11.56 ChemAxon pKa (Strongest Basic) -2.4 ChemAxon Physiological Charge 0 ChemAxon Hydrogen Acceptor Count 3 ChemAxon Hydrogen Donor Count 2 ChemAxon Polar Surface Area 75.27 Å2 ChemAxon Rotatable Bond Count 3 ChemAxon Refractivity 64.2 m3·mol-1 ChemAxon Polarizability 24.89 Å3 ChemAxon Number of Rings 2 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter Yes ChemAxon Veber's Rule No ChemAxon MDDR-like Rule No ChemAxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS Not Available Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available
Drug created at October 20, 2016 20:40 / Updated at June 12, 2020 16:53